Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TTPH, Tetraphase Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: HardToFind who wrote (64)	11/5/2017 1:44:26 AM
From: HardToFind	Read Replies (1) \| Respond to of 80

The Latest Press Release On Oral Dosing (11/2/2017): Presented data at IDWeek 2017 from the first study of the Company’s recently completed phase 1 program designed to evaluate drug exposure of oral eravacycline in an IV-to-oral dosing regimen. These results, along with data from subsequent trials in this phase 1 program, have allowed for the identification of an optimized IV-to-oral dosing regimen using the current oral eravacycline formulation which the company plans to advance into a phase 2 clinical trial in patients with complicated urinary tract infections. This study is anticipated to begin in the first half of 2018.